linjc16/ctgov huggingface dataset:
Multicenter Asthma Research Collaboration

Study Overview
=================
Brief Summary
-----------------
To study the epidemiology of emergency asthma by focusing on three Multicenter Asthma Research Collaboration (MARC) databases collected over a two-year period in adult and pediatric emergency departments.

Detailed Description
-----------------
BACKGROUND: The Multicenter Airway Research Collaboration (MARC) was created by 12 emergency physicians in May 1996 to determine the best management of acute asthma in the emergency department. The principal investigator of MARC, Dr. Carlos Camargo, formed the MARC Steering Committee to help guide this collaboration. The MARC Coordinating Center is based at the Massachusetts General Hospital (Boston, MA). Financial support for MARC has come from a variety of sources, including government, foundations, and industry. The NHLBI study used MARC databases. DESIGN NARRATIVE: Five representative aims were to: 1) characterize acute asthma management in urban emergency departments (EDs) and then compare current practice with that recommended in the 1997 national guidelines; 2) examine gender differences in acute asthma; 3) identify reasons why minority patients with asthma go to (and possibly prefer) the ED for their asthma care; 4) characterize important clinical subgroups, such as acute asthma among pregnant women and patients with sudden-onset severe acute asthma; and 5) examine risk factors for asthma hospitalization and for relapse after ED discharge. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Asthma, Lung Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Database of Patients Undergoing Cardiac Computed Tomographic Angiography at William Beaumont Hospital (CT DATABASE)

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to establish an overarching database of information containing historical, demographical, clinical, and intermediate and long-term outcome data from all William Beaumont Hospital (WBH) patients undergoing Cardiac Computed Tomographic Angiography (CCTA) testing for clinical or scientific reasons.

Detailed Description
-----------------
The principal goal of his project is to enable the study investigators to organize WBH research activity in the field of CCTA by concentrating data from all the patients who allow use of their data in one organized, audited and securely stored database. It will allow the ability to collect retrospective and prospective data from a number of different clinical systems and securely maintain patient medical record numbers for the reference on future projects as well as identification of patients with multiple studies and multiple follow-ups.

Official Title
-----------------
Database of Patients Undergoing Cardiac Computed Tomographic Angiography (CCTA)at William Beaumont Hospital

Conditions
-----------------
Acute Coronary Syndrome, Chest Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all retrospective patients who under went a CTA and were granted a waiver of consent all prospective patients CTA patients who gave informed consent. Exclusion Criteria: Non CTA patients Patients who refused participation.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To establish an overarching database of information containing historical, demographical, clinical, and intermediate and long-term outcome data from all WBH patients undergoing CCTA testing for clinical or scientific reasons. |  | annually for 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary artery disease, chest pain, CCTA
Ultrasound Imaging of Subarachnoidal Space in Newborn Infants

Study Overview
=================
Brief Summary
-----------------
Based on the ultrasound measurement of CSF/spinal cord ratio in neonates the investigators plan to define a normal range of CSF volume for 0-7 day old newborns. The investigators hypothise to be able to create an ultrasound measurement index/number to predict unsuccessful neonatalal LPs.

Detailed Description
-----------------
Based on the available literature the success rate of neonatal lumbar puncture (LP) is quite low (some articles reporting as low as 50% (unsuccessful LPs including dry taps and traumatic taps)). Firstly, the investigators would like to set a normal range of CSF:spine ratio (representing the amount of CSF at the expected level of LP) based on the measurements in neonates of different gestational age and postnatal age with assessing ventricular index (VI) on cranial US. In the next phase of the study the investigators plan to assess the subarachnoidal space/amount of CSF of those neonates whom need LP performed. The investigators hypothise to be able to create an ultrasound measurement index/number that would be able to predict unsuccessful LPs.

Official Title
-----------------
Ultrasound Imaging of the Subarachnoidal Space at the Lumbar Region in Preterm and Term Newborn Infants

Conditions
-----------------
Ultrasound, Newborn Infant

Intervention / Treatment
-----------------
* Other: Ultrasound imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All neonates born at the Obstretrics and Gynecology Department, University of Szeged and all treated neonates at the Neonatal Unit, Pediatric Department, University of Szeged Exclusion Criteria: Hemidynamical instability, Strict minimal handling (eg Pulmonary Hypertension, MAS etc), Total Body Coooling for HIE (Hypoxic Ischemic Encephalopathy)

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 7 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Ultrasound imaging|Ultrasound imaging of the lumbar spine/subarachnoidal space|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Normal lumbal CSF index in neonates | Normal range (amount/ratio) of CSF in neonates, influencing the following factors: gestational age, postnatal age, fluid intake, type of delivery. | From Day 1 to Day 7 |
Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)

Study Overview
=================
Brief Summary
-----------------
[Objectives] Objectives include following to capture safety and efficacy of LYNPARZA in actual clinical use. ADR development in actual clinical use Factors which may affect safety and efficacy ADRs not expected from Precautions for Use

Detailed Description
-----------------
The objective of the Clinical Experience Investigation (CEI) is to collect following data to characterise safety and efficacy of LYMPARZA Tablets 100mg and 150mg (LYMPARZA) in usual post-marketing use. Development of adverse drug reactions (ADRs) Factors which may affect safety and efficacy of LYMPARZA Development of adverse drug reactions (ADRs) unexpected from Precautions for Use of the LYMPARZA JPI

Official Title
-----------------
Lynparza Tablets 100mg, 150mg Clinical Experience Investigation (All Case Investigation) in Patients With Platinum-sensitive Relapsed Ovarian Cancer

Conditions
-----------------
Ovarian Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Maintenance treatment for patients with recurrent ovarian cancer, who are sensitive to platinum based chemotherapy Exclusion Criteria: -
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of ADRs regarding Bone marrow depression, ILD, new primary malignancies, Embryo-foetal toxicity and exposure in patient with renal impairment | To be calculated incidence of ADRs related to LYMPARZA during the observation period regarding Bone marrow depression, ILD, new primary malignancies, Embryo-foetal toxicity and exposure in patient with renal impairment | from baseline to 1 year | 
| Factors which may impact incidence of ADRs related to LYMPARZA during the observation period, analysed by patient demographic characteristics | Factors which may impact incidence of ADRs, analysed by patient demographic characteristic(past medical history, and concomitant disease etc) | from baseline to 1 year | 
| Incidence of ADRs not expected from Precautions for Use of LYNPARZA JPI | To be calculated incidence of ADRs related to LYMPARZA during the observation period not expected from Precautions for Use of LYNPARZA JPI | from baseline to 1 year |
Short-term Outcomes of Transanal Total Mesorectal Excision With Structured Training Curriculums in China

Study Overview
=================
Brief Summary
-----------------
Transanal total mesorectal excision (TaTME) is an alternative for mid-low rectal cancer. In China, this procedure has been performed in high-volume centers with structured training curriculums. This study aimed to evaluate the short-term outcomes during the initial implementation of the TaTME procedure in high-volume centers who followed structured training curriculums in China.

Official Title
-----------------
Short-term Outcomes of Transanal Total Mesorectal Excision With Structured Training Curriculums in China: Retrospective Study of the First Twenty-five Cases in Seven High-volume Centers

Conditions
-----------------
Rectal Cancer

Intervention / Treatment
-----------------
* Other: Procedure/Surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18 and 75 years American Society of Anesthesiologists (ASA) score I to III A biopsy proven histological diagnosis of rectal carcinoma Undergoing transanal total mesorectal excision Exclusion Criteria: Pregnant or lactating women Synchronous rectal carcinoma History of colorectal cancer or other malignant tumors Clinical evidence of metastasis Emergency procedure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>5 patients underwent TaTME under proctoring | Other: Procedure/Surgery<br>* Transanal Total Mesorectal Excision<br>|
| Group 2<br>the first 10 patients underwent TaTME without proctoring | Other: Procedure/Surgery<br>* Transanal Total Mesorectal Excision<br>|
| Group 3<br>the second 10 patients underwent TaTME without proctoring | Other: Procedure/Surgery<br>* Transanal Total Mesorectal Excision<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of anastomotic leakage | according to the International Rectal Cancer Study Group | thirty days after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of Defecation disorders | A Wexner score >10 indicated the existence of defecation dysfunction | 6 months after surgery | 
| incidence of positive distal resection margin | A positive distal resection margin (DRM) was diagnosed with the presence of tumor cells within 1mm from the DRM | 30 days after surgery | 
| incidence of positivecircumferential resection margin | The positive circumferential resection margin (CRM) was defined as the presence of tumor cells within 1 mm from the CRM | 30 days after surgery |
The Efficacy of Pulsed Dye Laser in Dermatophytosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Pulsed Dye Laser therapy are effective in the treatment of Cutaneous Dermatophytosis.

Detailed Description
-----------------
This study was conducted to determine the efficacy of Pulse Dye Laser in skin fungal infection, if this study showed that Laser could be effective, this would be introduced as a new treatment modality.

Official Title
-----------------
The Efficacy of Pulsed Dye Laser in Dermatophytosis

Conditions
-----------------
Cutaneous Dermatophytosis, Pulsed Dye Laser

Intervention / Treatment
-----------------
* Device: pulsed dye (585nm) laser therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Positive KOH Smear skin plaques Exclusion Criteria: Tinea Capitis,Onychomycosis Pregnancy and feeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: pulsed dye (585nm) laser therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| smear & culture of skin scrap |  |  |
Efficacy of Intramuscular Naloxone 0.4mg. in Prophylaxis of Intrathecal Morphine Induced Pruritus After Cesarean Section

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether intramuscular naloxone 0.4mg. is effective in prophylaxis of intrathecal morphine induced pruritus after cesarean section.

Official Title
-----------------
Efficacy of Intramuscular Naloxone 0.4mg. in Prophylaxis of Intrathecal

Conditions
-----------------
Morphine Adverse Reaction

Intervention / Treatment
-----------------
* Drug: naloxone
* Drug: normal saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient schedule for cesarean section ASA class 1 Exclusion Criteria: have contraindication for spinal block complicated pregnancy have history of drug abuse during pregnancy obesity BMI>35kg./m2

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: naloxone<br> | Drug: naloxone<br>* naloxone 0.4mg.(1 ml) intramuscular<br>* Other names: narcan;|
| Placebo Comparator: normal saline<br> | Drug: normal saline<br>* normal saline 1 ml IM<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| efficacy of intrathecal naloxone 0.4mg. in prophylaxis of intrathecal morphine induced pruritus after cesarean section |  | 24 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pruritus, intrathecal morphine
Efficacy of Opioid-free Anesthesia in Reducing Postoperative Pain in Chronic Pain Patients Undergoing Spinal Surgery

Study Overview
=================
Brief Summary
-----------------
The objective of this trial is to determine whether an opioid-free general anesthetic (OFA) technique utilizing ketamine, dexmedetomidine, and lidocaine infusions can help reduce postoperative pain in opiate-dependent chronic pain patients (CPPs) undergoing spine surgery when compared with traditional opioid-containing techniques. It is expected that this OFA regimen will have a measurable reduction on postoperative opioid consumption and pain scores in CPPs.

Official Title
-----------------
Efficacy of Opioid-free Anesthesia in Reducing Postoperative Pain in Chronic Pain Patients Undergoing Spinal Surgery: A Pilot Study

Conditions
-----------------
Chronic Pain, Anesthesia

Intervention / Treatment
-----------------
* Drug: Opioid-free general anesthetic
* Drug: Traditional general anesthetic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic pain > 6 months, opiate-using patients scheduled for thoracic or lumbar spinal surgery Exclusion Criteria: Pregnant or breastfeeding women, significant hepatic, renal or cardiac disease, allergy to any of the study drugs, inability to consent, respond to pain assessments or use the patient controlled analgesia device

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Opioid-free anesthetic (OFA) group<br> | Drug: Opioid-free general anesthetic<br>* An opioid-free general anesthetic technique utilizing dexmedetomidine, ketamine, and lidocaine infusions<br>|
| Active Comparator: Traditional Anesthesia (TA) group<br> | Drug: Traditional general anesthetic<br>* Traditional general anesthetic technique utilizing sufentanil, fentanyl or remifentanil<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantified opioid-consumption |  | 48 hours following surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual analogue scale (VAS) pain scores |  | 48 hours following surgery | 
| Time of stay in post-anesthetic care unit (PACU) |  | up to 5 hours following surgery | 
| Incidence of adverse events |  | 48 hours following surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Opioid-sparing
Interaction of Apelin and Angiotensin in the Systemic Circulation

Study Overview
=================
Brief Summary
-----------------
The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease. Apelin improves that pumping ability of the heart and we wish to know if this action persists in the presence of increased levels of angiotensin II.

Conditions
-----------------
Renin Angiotensin System

Intervention / Treatment
-----------------
* Drug: Angiotensin II
* Drug: Saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 18 years old Healthy volunteers Exclusion Criteria: Lack of informed consent Age < 18 years, Current involvement in other research studies, Systolic blood pressure >190 mmHg or <100 mmHg Malignant arrhythmias Renal or hepatic failure Haemodynamically significant aortic stenosis Severe or significant co morbidity Women of childbearing potential. Any regular medication Previous history of any cardiovascular disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Angiotensin II<br> | Drug: Angiotensin II<br>* Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.<br>|
| Placebo Comparator: Saline infusion<br> | Drug: Saline<br>* Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiac output |  | 90 mins | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Systemic haemodynamics |  | 90mins | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
renin-angiotensin system, apelin, systemic haemodynamics